TiGenix
Script error: No such module "Infobox".Template:Template otherScript error: No such module "Check for conflicting parameters".Script error: No such module "Check for unknown parameters".
TiGenix is a European cell therapy company with a proprietary validated allogeneic expanded adipose-derived stem cell (eASC) platform technology for the treatment of autoimmune and inflammatory diseases, and a commercialized product. Its corporate headquarters are in Leuven, Belgium, and it has operations in Madrid, Spain. TiGenix was founded in 2000 by Prof. Dr. Frank P. Luyten and Gil Beyen as a spin-off from the Katholieke Universiteit Leuven and the Ghent University.Script error: No such module "Unsubst".
TiGenix's therapeutic approach is to focus on the use of living cells rather than conventional drugs for the treatment of inflammatory and autoimmune diseases, through its eASC-based platform, and heart disease, through its CSC-based platform. TiGenix's pipeline of stem cell programs is based on validated platforms of allogeneic stem cells.Script error: No such module "Unsubst".
History
TiGenix has completed and received positive data in, a single pivotal Phase III trial in Europe of its most advanced product candidate Cx601, a potential first-in-class injectable allogeneic stem cell therapy indicated for the treatment of complex perianal fistulas in patients with Crohn's disease. On 28 July 2016 The Lancet published the results of their phase 3 ADMIRE-CD Trial.[1]
Acquisition by Takeda
In early January 2018, Takeda Pharmaceutical Company announced it would acquire TiGenix for up to €520 million ($632 million).[2]
References
External links
- TiGenix website
- 'Tigenix has been a rollercoaster', De Tijd, 14 May 2014
- Template:Replace on YouTubeScript error: No such module "Check for unknown parameters".
- 'Cx601 could be launched in 2017', L'Echo, 3 July 2014
- Template:Replace on YouTubeScript error: No such module "Check for unknown parameters".
- Template:Replace on YouTubeScript error: No such module "Check for unknown parameters".